Please use this identifier to cite or link to this item:
|Title:||Impact of DNA Patents in Pharmacogenomics Research and Development. Economic and Policy Issues|
|Authors:||PACI Daniele; HOPKINS Michael; ZIKA Eleni; IBARRETA RUIZ Dolores|
|Citation:||Drug Development Research vol. 71 no. 8 p. 485-491|
|Type:||Articles in periodicals and books|
|Abstract:||The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in recent years, and some technologies based on these developments have entered into use. It is notable that these advances have occurred in parallel with related advances in genetic testing, lead by developments in testing services for the diagnosis of rare disorders that share Mendelian patterns of inheritance. However, a profusion of patents on nucleotide sequences (often termed ¿gene patents¿) has led to widespread concern that disputes over intellectual property could hamper the development and diffusion of these technologies. This paper outlines the recent evidence from major empirical studies on the complex landscape of diagnostic DNA patents in the US and Europe, and discusses the traditional arguments in favour and against gene patenting in PGx and genetic testing. It also explores the extent to which concerns in clinical genetics might be relevant to PGx. We find that although recent evidence on genetic testing suggests that many of the issues might have been overestimated or overemphasized, no dedicated studies have been published on IP and PGx.|
|JRC Institute:||Growth and Innovation|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.